



Alzheimer’s disease (AD), the most prevalent cause of dementia, is a progressive neurodegenerative disorder marked by the abnormal accumulation of amyloid-beta (Aβ) plaques and neurofibrillary tau tangles. It currently affects more than 50 million individuals worldwide, with projections reaching over 210 million by 2050.1 While advancing age remains the dominant risk factor – affecting more than […]
Your clinical career is shaped not only by what you know, but by who helps you navigate what comes next. Join us for the final episode in our mini-series exploring non-clinical skills that can help you thrive in your clinical career. Today we explore how to develop the right team around you to support your […]
New X-TOLE2 findings highlight the potential of azetukalner in treatment-resistant focal epilepsy Despite a growing number of available therapies, many people with Focal epilepsy continue to experience uncontrolled seizures, highlighting the ongoing need for more effective and better tolerated treatment options. We met with American Academy of Neurology 2026, Prof. Jacqueline French (NYU Comprehensive Epilepsy […]
New international data support rapid aquaporin-4 antibody testing to improve earlier diagnosis and access to care in NMSOD Accurate and timely antibody testing remains central to improving outcomes in neuromyelitis optica spectrum disorder (NMOSD), where early diagnosis can help prevent irreversible disability and guide the use of highly specific therapies. At American Academy of Neurology […]
Why this topic matters Autoimmune psychosis (AP) is conceptualized as a psychosis-dominant form of autoimmune encephalitis (AE). In contrast to ‘typical’ AE, in which seizures, impaired consciousness and focal deficits rapidly declare a neurological syndrome, patients with AP can initially ...
We often focus on clinical excellence, but spend less time developing broader skills that could help us better lead with purpose and build more fulfilling, impactful careers. In this episode, part of a mini-series in partnership with LEADderm, Dr Jennifer Soung and Denise Mann explore how clinicians can engage with the media to educate, empower and extend their impact beyond the clinic.
Alzheimer’s disease (AD), the most prevalent cause of dementia, is a progressive neurodegenerative disorder marked by the abnormal accumulation of amyloid-beta (Aβ) plaques and neurofibrillary tau tangles. It currently affects more than 50 million individuals worldwide, with projections reaching over 210 ...
Neurologist Jessica Feldman, MD, and neurosurgeon Casey Halpern, MD, discuss how recent innovations are improving patient outcomes and expanding access to DBS for PD and ET patients in general neurology.
In this activity, watch a leading expert explain how to perform and score each of the mFARS test items with FA patients at varying levels of disease progression.
Share your knowledge, influence clinical practices and enhance patient care in Neurology today!
Whether you’re working in an agency, in a clinical role, or in academia, many healthcare professionals wonder what lies behind the doors of the pharmaceutical industry. In this episode, Gina is joined by Sian Kneller, Director of Global Content Design at GSK and Founder of The Agency Advantage, to unpack exactly what it takes to make the leap. With over 20 years’ experience, from medical writer to leading global medical affairs strategy, Sian now helps others make a successful move into pharma. In this episode she shares what the transition really looks like, which transferable skills matter most, and how you can stand out in a competitive field.
It is my pleasure to introduce the 2025 of touchREVIEWS in Neurology, which brings together an exceptional collection of reviews, original research and congress highlights that reflect the continued evolution of neurological science and clinical innovation. This issue opens with Jelle ...
Between 60% and 80% of cases with dementia worldwide are caused by Alzheimer’s disease (AD), making it the most prevalent type of dementia.1 As of 2025, approximately 60 million people worldwide are affected by dementia, and by 2050, projections suggest a rise to nearly 210 ...
Huntington’s disease (HD) is a fatal, autosomal-dominant, neurodegenerative disorder caused by a cytosine–adenine–guanine (CAG) trinucleotide repeat expansion in the huntingtin (HTT) gene, located on chromosome 4p16.3. When this repeat exceeds 36 units, it leads to the synthesis of ...
In this episode, Nicky speaks with Prof. Georgina Ellison-Hughes from King’s College London about the groundbreaking field of senolytics and their potential to advance the treatment of age-related diseases. From understanding the science behind cellular senescence to how senolytic drugs work and what early clinical trials reveal, this episode explores an exciting frontier in longevity medicine.
In general, headaches can be classified into primary headaches (where no underlying disease is found) and secondary headaches (where a predefined condition is the cause of the headache). According to the International Classification of Headache Disorders, third edition (ICHD-3), primary ...
Acute ischaemic stroke management Recent randomized controlled trials (RCTs) comparing bridging intravenous thrombolysis (IVT) with tissue plasminogen activator (tPA) to direct endovascular treatment (EVT) for large-vessel occlusion (LVO) strokes within 4.5 hours of onset have failed to show inferiority of direct ...
In this episode of Visionary Voices, we welcome Associate Professor Grace Vincent from CQUniversity’s Appleton Institute. A leading expert on sleep and shift work, Grace explores how disrupted sleep affects physician health in both the short and long term, as well as its impact on safety and performance. We also discuss what this means for patient outcomes and share practical strategies to manage sleep loss.
Epilepsy affects approximately 1% of the global population, with one-third of patients remaining refractory to medical therapy.1 Drug-resistant epilepsy (DRE), defined as the failure of two appropriately chosen antiseizure medications (ASMs) to achieve seizure freedom, poses significant risks, including injury and ...
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
In this episode of Visionary Voices, Dr Anthony Caggiano, Chief Medical Officer at Cognition Therapeutics, joins us to explore how biomarkers are transforming our understanding of Alzheimer’s disease, from diagnosis and disease progression to drug development and the future of clinical care.
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder of upper and lower motor neurons that results in progressive motor impairment. ALS is the most common disease of motor neurons with an annual incidence of approximately 1.7–2.5 per 100,000 people. It is a ...
Learn from leading experts about emerging outcome measures and biomarkers in spinal muscular atrophy (SMA).
In this activity, learn about diagnostic and predictive testing for amyotrophic lateral sclerosis (ALS), challenges and the evolving paradigm of care for people living with the disease.
Watch leading experts discuss evolving fluid biomarkers for AD and assess current blood biomarkers for diagnosing AD in the clinic.
Our inaugural touchNEUROLOGY Future Leaders 2025 campaign celebrates the next generation of neurologists shaping the future of clinical practice, research, and education.
Nominated by our Editorial Board and faculty, this diverse group of early-career specialists are driving innovation and impact across neurogenetics, digital diagnostics, brain health equity, and more. In exclusive interviews, they share their journeys, inspirations, and visions for the field’s future.
Dr Hannah Critchlow is a neuroscientist, bestselling author, broadcaster, and Science Outreach Fellow at Magdalene College, University of Cambridge, UK, and a powerful advocate for public understanding of neuroscience.
“Your brain thrives on connection; meeting people, interacting and sharing ideas is vital for not only your individual brain health but also our species survival.”
Dr Bjorn Logi Thorarinsson is a neurologist and stroke specialist from Iceland, recognized for his leadership in developing acute stroke care systems nationally and across Europe. He currently serves as Chief Operating Officer of the Stroke Action Plan for Europe, overseeing the largest improvement initiative of the European Stroke Organisation and Stroke Alliance for Europe.
“I learned from my father that there are no shortcuts, it is a balance of flexibility, persistence and resilience, demanding that one shall be no less comfortable with challenges than with reaching goals.”
Antonio Ciacciarelli is a vascular neurologist at the Stroke Unit of the Policlinico Umberto I University Hospital in Rome, Italy. He graduated in Medicine and Surgery from Sapienza University of Rome and completed his neurology residency at the University of Messina. He holds a PhD in Arterial Hypertension and Vascular Biology from Sapienza University. He has strong clinical and research focus on ischaemic stroke and reperfusion injury, his work bridges bedside care and translational science.
“Beyond clinical care and research, we also have the responsibility, and the privilege, to support and inspire the next generation. And that may be the most meaningful impact of all.”
Dr Bardia Nourbakhsh, Associate Professor of Neurology, Johns Hopkins University, Baltimore, MD, USA, is a rising star whose work bridges rigorous clinical neurological research with compassionate, patient-centred care. From his early fascination with the brain’s complexity to his current research into treatments for multiple sclerosis (MS)-related fatigue, Dr Nourbakhsh’s journey reflects a commitment to innovation, collaboration and improving lives.
“Seeing the remarkable progress in MS therapies over the past three decades convinced me that this is a field where rigorous science can rapidly change lives.”
Dr Ellis van Etten, vascular neurologist and clinical scientist at Leiden University Medical Center, specializes in cerebral amyloid angiopathy and other types of cerebral small vessel disease. With early research training at J. Philip Kistler Stroke Research Center at Massachusetts General Hospital, and a PhD on cerebral amyloid angiopathy at Leiden University, she is now actively contributing to international research, including participation in a multicentre phase II trial.
“The most exciting development for me is the growing potential to find a treatment for cerebral amyloid angiopathy, with several possible treatment targets now being identified.”
Introducing the Editorial Board of touchREVIEWS in Neurology, who support our mission to advance medical knowledge and practice by ensuring the integrity, relevance, and impact of the content we publish. Together, we strive to foster a vibrant academic community and contribute to the continuous improvement of healthcare worldwide.

Neuromuscular diseases

Professor and Division Chief for Neuromuscular Medicine, Department of Neurology, Keck School of Medicine, University of Southern California (USC), Los Angeles, CA, USA
Said R Beydoun, MD, FAAN, is Professor and Division Chief for Neuromuscular Medicine at the Department of Neurology at Keck School of Medicine, University of Southern California (USC). He is Program Director of the Clinical Neurophysiology Fellowship. As a principal investigator, Dr Beydoun has participated in multiple research clinical trials. His clinical and research areas of expertise in the field of neuromuscular medicine include amyotrophic lateral sclerosis (ALS), myasthenia gravis, peripheral neuropathy (including chronic inflammatory demyelinating polyneuropathy), multifocal motor neuropathy and transthyretin-related amyloid neuropathy. He has published in several scientific journals on topics related to neuromuscular diseases and is co-Editor-in-Chief of touchREVIEWS in Neurology. He is an elected fellow of the American Academy of Neurology and a fellow of the American Association of Neuromuscular and Electrodiagnostic Medicine; a member of the medical/scientific advisory board of the Myasthenia Gravis Foundation of America; Medical Director of the Certified ALS Treatment Center of Excellence at Keck USC; and holds board certification by the American Board of Psychiatry and Neurology in neurology, clinical neurophysiology, neuromuscular medicine and pain medicine.

Multiple sclerosis

Attending Neurologist, Cooper University Hospital, Cooper Neurological Institute, Cherry Hill, NJ, USA
Professor of Neurology, Cooper Medical School of Rowan University, Camden, NJ, USA
Emeritus Professor of Neurology, University of Nottingham, Nottingham, UK
Prof. Cris S Constantinescu is the co-Editor-in-Chief of touchREVIEWS in Neurology. Cris Constantinescu is Attending Neurologist at Cooper University Hospital, Cooper Neurological Institute, Cherry Hill, NJ, USA, Professor of Neurology at Cooper Medical School of Rowan University, Camden, NJ, USA, and Emeritus Professor of Neurology in the Academic Unit of Mental Health and Clinical Neurosciences at the University of Nottingham, Nottingham, UK. He graduated with an MD from Boston University School of Medicine, USA, in 1988. As a recipient of the physician-scientist award from the National Institutes of Health, USA, he completed a PhD in immunology at the University of Pennsylvania in 1998. He has completed an internship and a residency in neurology and fellowships in neuroimmunology and neurorehabilitation. He was appointed honorary consultant neurologist and senior lecturer in neurology at the University of Nottingham 2000–2001. In 2004, he was appointed Professor of Neurology and Chair in Neurology at the University of Nottingham, a post he held until 2021. He has authored or co-authored over 200 articles in international journals. His research interests are immune regulation in inflammatory diseases of the nervous system, in particular multiple sclerosis, neuroimaging, clinical trials and cognitive neurology. He is currently involved in the care of numerous patients with neuroimmunological and neurodegenerative diseases.

Movement disorders

Professor of Movement Disorders; Director, Neurology Clerkship Program, McGovern Medical School, UTHealth Houston, Houston, TX, USA
Dr Erin Furr-Stimming joined the Neurology faculty as an Assistant Professor in 2007 after completing her internship, residency and fellowship at McGovern Medical School-UTHealth. Her clinical expertise is evaluating and treating patients with Huntington’s disease (HD), Parkinson’s disease, atypical parkinsonian syndromes, focal and generalized dystonia, essential tremor and spasticity.
From 2011-2017, Dr Furr-Stimming she served as Chief of Neurology at Lyndon Baines Johnson (LBJ) Hospital. In 2016, she was awarded 1 of 39 designated Level 2 Huntington’s Disease Society of America (HDSA) Centers of Excellence in the country and the only one in Texas. She has focused her clinical efforts on helping those with this devastating neurological disorder and raising awareness through education. She is currently an Associate Professor and is also Director of the Neurology Clerkship Program.

Multiple sclerosis

Assistant Professor, University of Naples, Italy,
Consultant Neurologist, Policlinico University Hospital of Naples, Italy
Dr. Marcello Moccia is Assistant Professor at the University of Naples, Italy, and Consultant Neurologist at the Policlinico University Hospital of Naples, Italy. Dr. Moccia received his medical degree (MD) from University of Naples in 2010 and completed there his training in Neurology (2016) and PhD in Neuroscience (2019). He has further trained at the National Hospital for Neurology and Neurosurgery (London, UK), and has been awarded MD(Res) degree at UCL Queen Square Institute of Neurology (London, UK) (2020). His clinical and research interests are in the field of multiple sclerosis, including immunology, neuroimaging, epidemiology and translational applications. Dr. Moccia has authored over 200 peer-reviewed and indexed articles. He is Editorial Board Member of Neurology and Multiple Sclerosis Journal.
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
Keep track of your clinical interests and newsletter subscriptions.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Already registered? Login below.